Massimo Breccia

Via Benevento 6
Rome, 00161, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 540 publications

Targeting the hepcidin-ferroportin axis in polycythemia vera: a complementary approach to clone-directed therapies.

Targeting the hepcidin-ferroportin axis in polycythemia vera: a complementary approach to clone-directed therapies.

Journal: Blood reviews
Published: June 13, 2026

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Journal: Clinical lymphoma, myeloma & leukemia
Published: June 09, 2026

Describing the use of ruxolitinib for the treatment of myelofibrosis: a plain language summary of the ROMEI early study results.

Describing the use of ruxolitinib for the treatment of myelofibrosis: a plain language summary of the ROMEI early study results.

Journal: Future oncology (London, England)
Published: May 22, 2026

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants.

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants.

Journal: European journal of haematology
Published: April 27, 2026

Is There Still a Role for Autologous Stem Cell Transplantation in Older Adults with AML?

Is There Still a Role for Autologous Stem Cell Transplantation in Older Adults with AML?

Journal: Hematology reports
Published: April 24, 2026

Four Decades of Molecular Innovation in Chronic Myeloid Leukemia: From Antisense Targeting to Treatment-Free Remission.

Four Decades of Molecular Innovation in Chronic Myeloid Leukemia: From Antisense Targeting to Treatment-Free Remission.

Journal: Cancers
Published: April 06, 2026

CD56+/CD38+ Neutrophils: Rapid and Specific Flow Cytometric Signature for Chronic Myeloid Leukemia.

CD56+/CD38+ Neutrophils: Rapid and Specific Flow Cytometric Signature for Chronic Myeloid Leukemia.

Journal: Mediterranean journal of hematology and infectious diseases
Published: March 31, 2026

Multidisciplinary characterization of rare MPL Y591 and R592 variants in myeloid disorders: from clinical correlation and literature-based evidence to in silico predictors and structural bioinformatics.

Multidisciplinary characterization of rare MPL Y591 and R592 variants in myeloid disorders: from clinical correlation and literature-based evidence to in silico predictors and structural bioinformatics.

Journal: Experimental hematology
Published: March 24, 2026

ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.

ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.

Journal: Leukemia
Published: March 20, 2026

Frontline Nilotinib Versus Dasatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Propensity Score Analysis Based on Agenzia Italiana del Farmaco Monitoring Registries.

Frontline Nilotinib Versus Dasatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Propensity Score Analysis Based on Agenzia Italiana del Farmaco Monitoring Registries.

Journal: Clinical lymphoma, myeloma & leukemia
Published: March 15, 2026

Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.

Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.

Journal: Leukemia
Published: March 05, 2026

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

Journal: Blood advances
Published: February 27, 2026
Showing 1-12 of 540

Last Updated: 09/26/2026